The novel FAK inhibitors 10k or 10l, significantly reduced p-FAK levels and exhibited potent antitumor activity in both EGFR-TKI-sensitive and -resistant NSCLC cells harboring activating EGFR mutations, in vitro and in vivo. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.